MolecuLight Announces Groundbreaking Study on Antimicrobial Stewardship in Wound Care

Dr. Serena, a dedicated advocate in the fight against antimicrobial resistance, shares his insights: "Antimicrobial resistance is a critical challenge across all areas of medicine, including wound care. Our study represents a significant advancement in tackling this issue. We discovered that using fluorescence imaging during patient assessments reduced the average number of concurrent medications prescribed—from 1.4 per patient with standard clinical examination to just 1 per patient. Additionally, systemic antibiotics made up only 8% of prescriptions in the fluorescence group, compared to 36% in the standard care group."

He continues, "Our research highlights a notable shift towards topical prescriptions in the fluorescence imaging group (92%) compared to standard care (64%). These results emphasize the profound impact of real-time diagnostic technologies. In this case, MolecuLight enabled clinicians to make immediate and informed decisions, reducing the reliance on systemic antibiotics and reinforcing the efficacy of localized treatments, as supported by extensive research."

Anil Amlani, CEO of MolecuLight, also commented on this groundbreaking research: "This study underscores the transformative power of MolecuLight as a real-time bacterial detection tool. By providing objective and actionable information directly at the bedside, our devices significantly reduce antibiotic misuse, making MolecuLight a critical component of effective antimicrobial stewardship programs (ASPs)." He added, " Our technology is instrumental in combating overprescribing and enhancing patient outcomes. This new research suggests that MolecuLight has an important role to play in addressing one of the most concerning and pressing public health issues to date, reinforcing its value to healthcare providers managing wounds and emphasizing our commitment to advancing health care practices."

To access the full publication, follow this link: https://doi.org/10.3390/diagnostics14182034.

About MolecuLight Inc. 

MolecuLight Inc. is a privately owned medical imaging company with a global presence that manufactures and commercializes the MolecuLight i:X^®and DX^™wound imaging devices. These are the only class II FDA-clearedpoint-of-care imaging devices for the real-time detection of elevated bacterial burden in wounds. They also provide accurate digital wound measurement for comprehensive wound management, supported by strong clinical evidence including over 100 peer-reviewed publications.

For sales, media or other inquiries or further information, please contact
Hunter Zudans 
Director of Marketing
MolecuLight Inc.
T. +1.484.682.7580
[email protected]
www.moleculight.com 

View original content:https://www.prnewswire.co.uk/news-releases/moleculight-announces-groundbreaking-study-on-antimicrobial-stewardship-in-wound-care-302269713.html